Mirae Asset Global Investments Co. Ltd. Has $617,000 Stake in GH Research PLC (NASDAQ:GHRS)

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of GH Research PLC (NASDAQ:GHRS) by 14.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 106,363 shares of the company’s stock after buying an additional 13,579 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in GH Research were worth $617,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. RTW Investments LP boosted its holdings in GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after acquiring an additional 1,158,172 shares during the last quarter. Lynx1 Capital Management LP boosted its holdings in GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after acquiring an additional 133,804 shares during the last quarter. Barclays PLC boosted its holdings in GH Research by 98.2% during the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after acquiring an additional 31,500 shares during the last quarter. Finally, PEAK6 Investments LLC boosted its holdings in GH Research by 72.9% during the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after acquiring an additional 16,991 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on GHRS. JMP Securities lowered their target price on GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Monday, March 4th.

GH Research Price Performance

NASDAQ GHRS opened at $10.50 on Friday. The stock has a market capitalization of $546.32 million, a price-to-earnings ratio of -15.44 and a beta of 0.84. GH Research PLC has a one year low of $5.05 and a one year high of $14.64. The business’s fifty day moving average is $9.97 and its 200-day moving average is $7.88.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Research analysts expect that GH Research PLC will post -0.96 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).